Why the study?
Sub-clinical inflammation and defective HDL function are potential risk factors for a first cardiovascular event, but their role in STEMI patients lacking standard modifiable cardiovascular risk factors was unclear.
Are sub-clinical inflammation and defective cholesterol efflux associated with SMuRF-less status and 1-year mortality in STEMI patients?
Are sub-clinical inflammation and defective cholesterol efflux associated with SMuRF-less status and 1-year mortality in STEMI patients?
In STEMI patients without standard modifiable risk factors, sub-clinical inflammation and defective cholesterol efflux are prevalent and independently associated with increased 1-year all-cause mortality.
Answers are grounded in this paper and cite their sources.
Cautious interpretation warranted in SMuRF-less STEMI; leaves open whether targeting inflammation or efflux improves survival.
AIMS: Sub-clinical inflammation and defective HDL function have emerged as potential risk factors for a first cardiovascular event. We evaluated their role in the pathogenesis of ST-segment elevation myocardial infarction (STEMI) patients with no standard modifiable cardiovascular risk factors (SMuRF). METHODS AND RESULTS: Using our STEMI biobank registry, we compared baseline characteristics and markers of sub-clinical inflammation [interleukin (IL)-1β, high-sensitivity C-reactive protein (hs-CRP), and defective HDL function using serum cholesterol efflux capacity] in patients with and without SMuRF. Determinants of 1-year all-cause mortality were assessed using multivariable Cox regression analyses. Among the 1604 patients included, 178 (11.1%) were SMuRF-less. Compared with patients with SMuRF, SMuRF-less patients had lower serum cholesterol efflux capacity (0.79 ± 0.16 vs. 0.83 ± 0.16, respectively, P < 0.001) and were more often in the highest tertile of IL-1β (28.7 vs. 18.9%, respectively, P = 0.002) with a trend towards more patients within the highest hs-CRP level tertile (24.7 vs. 19.1%, respectively, P = 0.077). Crude rates of mortality were higher in the SMuRF-less group (18.5 vs. 7.7%, P < 0.001). After multivariable adjustment with traditional prognostic risk factors, high tertiles of hs-CRP [hazard ratio, HR 1.83 (1.28-2.63), P = 0.001] or IL-1β [HR 1.54 (1.06-2.24), P = 0.024] and SMuRF-less status [HR 1.56 (1.05-2.38) P = 0.029] were associated with mortality, while higher serum cholesterol efflux capacity was protective [HR 0.27 (0.09-0.87), P = 0.028]. CONCLUSION: Sub-clinical inflammation and defective cholesterol efflux were associated with SMuRF-less status of STEMI patients and had prognostic impact. This highlights the need to explore new therapeutic strategies in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Roule et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: